291 related articles for article (PubMed ID: 28800937)
1. Vortioxetine: A new alternative for the treatment of major depressive disorder.
Salagre E; Grande I; Solé B; Sanchez-Moreno J; Vieta E
Rev Psiquiatr Salud Ment (Engl Ed); 2018; 11(1):48-59. PubMed ID: 28800937
[TBL] [Abstract][Full Text] [Related]
2. Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder.
Al-Sukhni M; Maruschak NA; McIntyre RS
Expert Opin Drug Saf; 2015 Aug; 14(8):1291-304. PubMed ID: 26022537
[TBL] [Abstract][Full Text] [Related]
3. Vortioxetine: a New Treatment for Major Depressive Disorder.
Connolly KR; Thase ME
Expert Opin Pharmacother; 2016; 17(3):421-31. PubMed ID: 26679430
[TBL] [Abstract][Full Text] [Related]
4. Role of vortioxetine in the treatment of neuropathic pain.
Alcántara Montero A; Pacheco de Vasconcelos SR
Rev Esp Anestesiol Reanim (Engl Ed); 2022 Dec; 69(10):640-648. PubMed ID: 36241510
[TBL] [Abstract][Full Text] [Related]
5. Using early changes in cold cognition to predict response to vortioxetine in major depressive disorder.
Park C; Zuckerman H; Subramaniapillai M; Mansur RB; Rosenblat JD; Cao B; Iacobucci M; Lee Y; Levitan R; Blumberger DM; McIntyre RS
Psychiatry Res; 2020 Feb; 284():112767. PubMed ID: 31978627
[TBL] [Abstract][Full Text] [Related]
6. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder.
Gonda X; Sharma SR; Tarazi FI
Expert Opin Drug Discov; 2019 Jan; 14(1):81-89. PubMed ID: 30457395
[TBL] [Abstract][Full Text] [Related]
7. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine.
Nierenberg AA; Loft H; Olsen CK
J Affect Disord; 2019 May; 250():35-42. PubMed ID: 30826492
[TBL] [Abstract][Full Text] [Related]
8. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
Fourrier C; Sampson E; Mills NT; Baune BT
Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
[TBL] [Abstract][Full Text] [Related]
9. Vortioxetine for the treatment of major depressive disorder.
Tritschler L; Felice D; Colle R; Guilloux JP; Corruble E; Gardier AM; David DJ
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):731-45. PubMed ID: 25166025
[TBL] [Abstract][Full Text] [Related]
10. Perspectives on the impact of vortioxetine on the treatment armamentarium of major depressive disorder.
Cuomo A; Barillà G; Cattolico M; Pardossi S; Mariantoni E; Koukouna D; Carmellini P; Fagiolini A
Expert Rev Neurother; 2024 May; 24(5):465-476. PubMed ID: 38536761
[TBL] [Abstract][Full Text] [Related]
11. VORTIOXETINE - THE NEW ANTIDEPRESSANT AGENT WITH PROCOGNITIVE PROPERTIES.
Dziwota E; Olajossy M
Acta Pol Pharm; 2016 Nov; 73(6):1433-1437. PubMed ID: 29634095
[TBL] [Abstract][Full Text] [Related]
12. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
Baune BT; Sluth LB; Olsen CK
J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
[TBL] [Abstract][Full Text] [Related]
13. The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Rosenblat JD; Kakar R; McIntyre RS
Int J Neuropsychopharmacol; 2015 Jul; 19(2):. PubMed ID: 26209859
[TBL] [Abstract][Full Text] [Related]
14. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram.
Levada OA; Troyan AS
J Affect Disord; 2019 May; 250():114-122. PubMed ID: 30852363
[TBL] [Abstract][Full Text] [Related]
15. Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine.
Orsolini L; Tomasetti C; Valchera A; Iasevoli F; Buonaguro EF; Fornaro M; Fiengo ALC; Martinotti G; Vellante F; Matarazzo I; Vecchiotti R; Perna G; Di Nicola M; Carano A; Di Bartolomeis A; De Giannantonio M; De Berardis D
CNS Neurol Disord Drug Targets; 2017; 16(1):65-92. PubMed ID: 27781949
[TBL] [Abstract][Full Text] [Related]
16. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data.
Sanchez C; Asin KE; Artigas F
Pharmacol Ther; 2015 Jan; 145():43-57. PubMed ID: 25016186
[TBL] [Abstract][Full Text] [Related]
17. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.
Chokka P; Bougie J; Proulx J; Tvistholm AH; Ettrup A
CNS Spectr; 2019 Dec; 24(6):616-627. PubMed ID: 30802419
[TBL] [Abstract][Full Text] [Related]
18. Vortioxetine in management of major depressive disorder - a favorable alternative for elderly patients?
Danielak D
Expert Opin Pharmacother; 2021 Jun; 22(9):1167-1177. PubMed ID: 33650935
[No Abstract] [Full Text] [Related]
19. Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD).
Chokka P; Bougie J; Rampakakis E; Proulx J
CNS Spectr; 2019 Jun; 24(3):338-347. PubMed ID: 29792585
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of vortioxetine on the physical symptoms of major depressive disorder.
Christensen MC; Florea I; Lindsten A; Baldwin DS
J Psychopharmacol; 2018 Oct; 32(10):1086-1097. PubMed ID: 30047820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
